



Retrophin, Inc. to Hold Third Quarter Operational and Financial Results Conference Call On Monday, November 18, 2013 at 4:30pm EST

November 15, 2013

NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) announced today that management will host a conference call and webcast, to discuss its operational and financial results for the period ended September 30, 2013, on Monday, November 18, 2013 at 4:30pm EST. The Company filed its form 10-Q on November 13, 2013.

Access information:

Date: Monday, November 18, 2013
Time: 4:30 pm EST
Dial-in numbers: 877-703-6109 (U.S. and Canada) or 857-244-7308
Conference ID number: 63839921
Live web cast: www.retrophin.com, under "Investor Relations"

The teleconference replay will be available from 8:30 pm EST on Monday, November 18, 2013 through 11:59 pm EST on Monday, November 25, 2013. The replay number is 888-286-8010 (U.S. and Canada) or 617-801-6888, confirmation code 59828006.

About Retrophin

Retrophin is a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Duchenne Muscular Dystrophy. Retrophin's lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for the treatment of FSGS during 2013. For additional information, please visit www.retrophin.com.

Retrophin, Inc.
Marc Panoff, 646-564-3671
CFO
marc@retrophin.com
or
Investors
Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

Source: Retrophin, Inc.

News Provided by Acquire Media